Thermo Fisher Scientific (TMO)
(Delayed Data from NYSE)
$596.92 USD
+3.13 (0.53%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $596.52 -0.40 (-0.07%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$596.92 USD
+3.13 (0.53%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $596.52 -0.40 (-0.07%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth D Momentum D VGM
Zacks News
National Vision's (EYE) Q3 Earnings Top Estimates, View Raised
by Zacks Equity Research
National Vision's (EYE) third-quarter performance reflects strong growth in core business segments.
Option Care Health (BIOS) Q3 Earnings Meet, Revenues Top
by Zacks Equity Research
Albeit Option Care Health (BIOS) is yet to reap material benefits from its merger-related synergies, the reporting of a positive gross margin in third-quarter results is encouraging for investors.
DENTSPLY SIRONA (XRAY) Beats on Q3 Earnings, Ups '19 View
by Zacks Equity Research
DENTSPLY SIRONA (XRAY) gains from solid segmental contributions in Q3.
Globus Medical (GMED) Q3 Earnings Meet Mark, Revenue View Up
by Zacks Equity Research
Globus Medical (GMED) reports robust top-line numbers for the third quarter on segmental strength.
Hologic's (HOLX) Q4 Earnings Meet, Revenues Top Estimates
by Zacks Equity Research
Hologic (HOLX) exhibits robust fourth-quarter growth fueled by strong segmental performance.
Cardinal Health (CAH) Q1 Earnings & Revenues Beat Estimates
by Zacks Equity Research
Cardinal Health (CAH) Q1 results benefit revenue growth and strong segmental performance. However, contraction in gross margin remains a concern.
AmerisourceBergen (ABC) Q4 Earnings & Revenues Beat Estimates
by Zacks Equity Research
AmerisourceBergen's (ABC) Q4 earnings benefit from higher revenues, segmental growth and strong fiscal 2020 outlook.
Insulet (PODD) Beats on Q3 Earnings, Ups '19 Revenue View
by Zacks Equity Research
Insulet's (PODD) year-over-year improvement in Q3 revenues on the solid uptake of Omnipod system both in the United States and across international markets looks promising.
OPKO Health (OPK) Q3 Earnings Miss Estimates, Revenues Beat
by Zacks Equity Research
OPKO Health (OPK) third-quarter results benefit from higher Product revenues and RAYALDEE prescription growth.
CVS Health (CVS) Beats on Q3 Earnings, Raises '19 EPS Guidance
by Zacks Equity Research
CVS Health's (CVS) strong year-over-year growth in the top line is aided by a robust performance at the Pharmacy Services segment.
Phibro's (PAHC) Q1 Earnings & Revenues Fall Y/Y, Margins Down
by Zacks Equity Research
Phibro (PAHC) exhibits a dismal first-quarter performance on a decline in revenues at core business segments.
HMS Holdings (HMSY) Q3 Earnings Top Estimates, Revenues Miss
by Zacks Equity Research
HMS Holdings' (HMSY) Q3 earnings benefit from higher revenues at Analytical Services unit and strong 2019 outlook.
Avanos (AVNS) Earnings and Revenues Miss Estimates in Q3
by Zacks Equity Research
Avanos (AVNS) third-quarter results benefit from higher revenues and strong segmental performance.
Zacks.com featured highlights include: SYNNEX, Thermo Fisher Scientific, Allstate, Intel and Target
by Zacks Equity Research
Zacks.com featured highlights include: SYNNEX, Thermo Fisher Scientific, Allstate, Intel and Target
Inogen's (INGN) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Softness in domestic and international business-to-business revenues impact Inogen's (INGN) Q3 results.
DaVita (DVA) Earnings and Revenues Beat Estimates in Q3
by Zacks Equity Research
DaVita (DVA) raises guidance for 2019 following impressive Q3 results.
STERIS' (STE) Q2 Earnings Surpass Estimates, FY20 View Up
by Zacks Equity Research
STERIS (STE) witnesses solid revenue growth across each of its operating segments in the second quarter of fiscal 2020.
Zimmer Biomet (ZBH) Q3 Earnings Top, Operating Margin Falls
by Zacks Equity Research
Zimmer Biomet (ZBH) gains from strong sales growth across all geographies and most operating segments in Q3.
Hill-Rom's (HRC) Q4 Earnings Beat on Strong Global Sales
by Zacks Equity Research
Internationally, Asia Pacific, Latin America and EMEA registers strong revenue growth for Hill-Rom (HRC).
Allscripts (MDRX) Q3 Earnings Beat Estimates, Improve Y/Y
by Zacks Equity Research
Allscripts (MDRX) third-quarter results gain from growth in bookings and solid segmental performance. Contraction in both gross and operating margins remains a woe.
Luminex (LMNX) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Luminex's (LMNX) Q3 earnings benefit from higher revenues and solid performance across System Sales, Consumable Sales and Service Revenues. However, gross margin contraction remains a woe.
Myriad Genetics (MYGN) Lags Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Myriad Genetics (MYGN) observes a decline in Hereditary Cancer, GeneSight, Vectra as well as Other testing revenues in Q1.
Henry Schein (HSIC) Q3 Earnings Top Estimates, Revenues Lag
by Zacks Equity Research
Henry Schein (HSIC) registers solid performance across its key operating businesses in Q3.
Becton, Dickinson (BDX) Beats on Q4 Earnings and Revenues
by Zacks Equity Research
Becton, Dickinson (BDX) gains from solid segmental contributions in Q4.
Tandem Diabetes (TNDM) Q3 Loss Narrows Y/Y, Sales Improve
by Zacks Equity Research
Tandem Diabetes (TNDM) exhibits a robust performance in the third quarter of 2019, fueled by strong domestic demand.